Conference Review
Potential markers for AF, ROP and RRD
Studies on CRA message for CRAO, ranibizumab biosimilar switch and in-office pneumatic retinopexy also highlighted ASRS 2024.
Trial updates in GA, MacTel type 2 and DME
Four ASRS abstracts look at ANX007, pegcetacoplan, encapsulated cell therapy and tarcocimab.
Update on mitochondrial stabilizers
Also from the Angiogenesis, Exudation, and Degeneration meeting, emerging treatments for nAMD and MacTel2, and a marker for anti-VEGF success in ROP.
AAO highlights: ILM peel in DR and more
Standout Retina Subspecialty Day 2022 talks include real-world faricimab and high-dose aflibercept results, and Protocol T outcomes.
Comparing techniques for RRD, MH
Prime cuts from ASRS also include a quick-response program for CRAO, and trials of agents for GA and mydriasis reversal.
Current Issue
Continuing Medical Education
Additional Publications
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Sponsored by Regeneron
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
Eyepoint Yutiq: A Discussion Among Experts on the Treatment of Uveitis Affecting the Posterior Segment
